RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/36928177http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/36928177http://www.w3.org/2000/01/rdf-schema#comment"Aurora A plays a critical role in G2/M transition and mitosis, making it an attractive target for cancer treatment. Aurora A inhibitors showed remarkable antitumor effects in preclinical studies, but unsatisfactory outcomes in clinical trials have greatly limited their development. In this study, the Aurora A inhibitor alisertib upregulated programmed death ligand 1 (PD-L1) expression in a panel of tumor cells both in vitro and in vivo. Upregulation of the checkpoint protein PD-L1 reduced antitumor immunity in immune-competent mice, paradoxically inhibiting the antitumor effects of alisertib. Mechanistically, Aurora A directly bound to and phosphorylated cyclic GMP-AMP synthase (cGAS), suppressing PD-L1 expression in tumor cells. Aurora A inhibition by alisertib activated the cGAS/stimulator of IFN genes (STING)/NF-κB pathway and promoted PD-L1 expression. Combining alisertib with anti-PD-L1 antibody improved antitumor immunity and enhanced the antitumor effects of alisertib in immune-competent mice. Our results, which reveal the immunomodulatory functions of Aurora A inhibitors and provide a plausible explanation for the poor clinical outcomes with their use, offer a potential approach to improve the antitumor efficacy of these inhibitors."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.org/dc/terms/identifier"doi:10.1172/jci161929"xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Huang J."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Jiang W."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Li Z."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Liu F."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Zhang Y."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Wang J."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Wang X."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Yu J."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Yu Q."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Zhu Z."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Wang R."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Hou J."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Dang Y."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/author"Shim J.S."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/date"2023"xsd:gYear
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/name"J Clin Invest"xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/pages"e161929"xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/title"Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression."xsd:string
http://purl.uniprot.org/citations/36928177http://purl.uniprot.org/core/volume"133"xsd:string
http://purl.uniprot.org/citations/36928177http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/36928177
http://purl.uniprot.org/citations/36928177http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/36928177
http://purl.uniprot.org/uniprot/#_B2R6Z3-mappedCitation-36928177http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/36928177